參考文獻 |
1. Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345, 41–52.
2. Roingeard, P.; Hourioux, C. Hepatitis C virus core protein, lipid droplets and steatosis. J. Viral Hepat. 2008, 15, 157–164.
3. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 2003, 58, 1–16.
4. Pawlotsky, J. M.; Gish, R. G. Future therapies for hepatitis C. Antivir. Ther. 2006, 11, 397–408.
5. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989, 244, 359–362.
6. Hoofnagle, J. H. Course and outcome of hepatitis C. Hepatology 2002, 36, S21–S29.
7. Simmonds, P. Genetic diversity and evolution of hepatitis C virus – 15 years on. J. Gen. Virol. 2004, 85, 3173–3188.
8. Simmonds, P.; Bukh, J.; Combet, C.; Deléage, G.; Enomoto, N.; Feinstone, S,; Halfon, P,; Inchauspé, G.; Kuiken, C.; Maertens, G.; Mizokami, M.; Murphy, D. G.; Okamoto, H.; Pawlotsky, J. M.; Penin, F.; Sablon, E.; Shin-I, T.; Stuyver, L. J.; Thiel, H. J.; Viazov, S.; Weiner, A. J.; Widell, A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42, 962–973.
9. Di Bisceglie, A. M.; Hoofnagle, J. H. Optimal therapy of hepatitis C. Hepatology 2002, 36, S121–S127.
10. Zein, N. N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol. 2005, 42, 315–322.
11. Bretner, M. Existing and future therapeutic options for hepatitis C virus infection. Acta Biochim. Pol. 2005, 52, 57–70.
12. Manns, M. P.; Foster, G. R.; Rockstroh, J. K.; Zeuzem, S.; Zoulim, F.; Houghton, M. The way forward in HCV treatment – finding the right path. Nat. Rev. Drug Disc. 2007, 6, 991–1000.
13. Hirashima, S.; Suzuki, T.; Ishida, T.; Noji, S.; Yata, S.; Ando, I.; Komatsu, M.; Ikeda, S.; Hashimoto, H. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure–activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J. Med. Chem. 2006, 49, 4721–4736.
14. Hwang, J. S.; Kregler, O.; Schilf, R.; Bannert, N.; Drach, J. C.; Townsend, L. B.; Bogner, E. Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleosides with enhanced activity against human cytomegalovirus. J.Virol. 2007, 81, 11604–11611.
15. Warren, T. K.; Warfield, K. L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus. A. S.; Kinch, M. S.; Goldblatt, M.; Aman M. J.; Bavari S. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents Chemother. 2010, 54, 2152–2159.
16. Ito, C.; Itoigawa, M.; Mishina, Y.; Filho, V. C.; Enjo, F.; Tokuda, H.; Nishino, H.; Furukawa, H. Chemical constituents of Calophyllum brasiliense. 2. structure of three new coumarins and cancer chemopreventive activity of 4-substituted coumarins. J. Nat. Prod. 2003, 66, 368–371.
17. Chilin, A.; Battistutta, R.; Bortolato, A.; Cozza, G.; Zanatta, S.; Poletto, G.; Mazzorana, M.; Zagotto, G.; Uriarte, E.; Guiotto, A.; Pinna, L. A.; Meggio, F.; Moro, S. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure–activity relationships. J. Med. Chem. 2008, 51, 752–759.
18. Robert, S.; Bertolla, C.; Masereel, B.; Dogné, J. M.; Pochet, L. Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J. Med. Chem. 2008, 51, 3077–3080.
19. Kamal, A.; Ramulu, P.; Srinivas, O.; Ramesh, G.; Kumar, P. P. Synthesis of C8-linked pyrrolo[2,1-c][1,4]benzodiazepinebenzimidazole conjugates with remarkable DNA-binding affinity. Bioorg. Med. Chem. Lett. 2004, 14, 4791–4794.
20. Chauhan, P. M. S.; Martins, C. J. A.; Horwell, D. C. Synthesis of novel heterocycles as anticancer agents. Bioorg. Med. Chem. 2005, 13, 3513–3518.
21. Demirayak, S.; Mohsen, U. A.; Karaburun, A. C. Synthesis and anticancer and anti-HIV testing of some pyrazino[1,2-a]benzimidazole derivatives. Eur. J. Med. Chem. 2002, 37, 255–260.
22. Garuti, L.; Roberti, M.; Malagoli, M.; Rossi, T.; Castelli, M. Synthesis and antiproliferative activity of some benzimidazole-4,7-dione derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 2193–2195.
23. Lukevics, E.; Arsenyan, P.; Shestakova, I.; Domracheva, I.; Nesterova, A.; Pudova, O. Synthesis and antitumour activity of trimethylsilylpropyl substituted benzimidazoles. Eur. J. Med. Chem. 2001, 36, 507–515.
24. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C. O.; Gediya, L. K.; Kataria, R.; Chopra, P., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. H. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 2005, 48, 2972–2984.
25. Curini, M.; Epifano, F.; Maltese, F.; Marcotullio, M.C.; Gonzales, S.P.; Rodriguez, J.C. Synthesis of collinin, an antiviral coumarin. Aust. J. Chem. 2003, 56, 59–60.
26. Bretner, M.; Baier, A.; Kopanska, K.; Najda, A.; Schoof, A.; Reinholz, M.; Lipniacki, A.; Piasek, A.; Kulikowsi, T.; Borowski, P. Synthesis and biological activity of 1H-benzotriazole and 1Hbenzimidazole analoguessinhibitors of the NTPase/helicase of HCV and of some related Flaviviridae. AntiViral Chem. Chemother. 2005, 16, 315–326.
27. Komazin, G.; Ptak, R. G.; Emmer, B. T.; Townsend, L. B.; Drach, J. C. Resistance of human cytomegalovirus to D- and L-Ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. Nucleotides Nucleic Acids 2003, 22, 1725–1727.
28. Beaulieu, P. L.; Bousquet, Y.; Gauthier, J.; Gillard, J.; Marquis, M.; McKercher, G.; Pellerein, C.; Valois, S.; Kukolj, G. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 Cells. J. Med. Chem. 2004, 47, 6884–6892.
29. Beaulieu, P. L.; Bös, M.; Bousquet, Y.; DeRoy, P.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; McKercher, G.; Poupart, M.-A.; Valois, S.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 2004, 14, 967–971.
30. Hwu, J. R.; Singha, R.; Hong, S. C.; Chang, Y. H.; Das, A. R.; Vliegen, I.; DeClercq, E.; Neyts, J. Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res. 2008, 77, 157–162.
31. Neyts, J.; Clercq, E. D.; Singha, R.; Chang, Y. H.; Das, A. R.; Chakraborty, S. K.; Hong, S. C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J. R. Structure–activity relationship of new anti-hepatitis C virus agents: heterobicycle–coumarin conjugates. J. Med. Chem. 2009, 52, 1486–1490.
32. De Clercq, E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discovery. 2007, 6, 1001–1018.
33. De Francesco, R.; Carfi, A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Delivery Rev. 2007, 59, 1242–1262.
34. Galeone, A.; Mayol, L.; Oliviero, G.; Piccialli, G.; Varra M. Synthesis of a new N1-pentyl analogue of cyclic inosine diphosphate ribose(cIDPR) as a stable potential mimic of cyclic ADP ribose (cADPR). Eur. J. Org. Chem. 2002, 24, 4234–4238.
35. Moore, C. L.; Chiaramonte, M.; Higgins, T.; Kuchta, R. D. Synthesis of nucleotide analogues that potently and selectively inhibit human DNA primase. Biochemistry, 2002, 41, 14066–14075.
36. Long, M. C.; Parker, W. B. Structure–activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobaterium tuberculosis. Biochem. Pharmacol. 2006, 71, 1671–1682.
37. Ottria, R.; Casati, S.; Manzocchi, A.; Baldoli, E.; Mariotti, M.; Maier. A. M.; Ciuffreda, P. Synthesis and evaluation of in vitro anticancer activity of some novel isopentenyladenosine derivatives. Bioorg. Med. Chem. 2010, 18, 4249–4254.
38. Hyde, R. M.; Broom, A. D.; Buckheit, R. W. Antiviral amphipathic oligo- and polyribonucleotides: analogue development and biological studies. J. Med. Chem. 2003, 46, 1878–1885.
39. Ikejiri, M.; Saijo, M.; Morikawa, S.; Fukushi, S.; Mizutani, T.; Kurane, I.; Maruyama, T. Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents. Bioorg. Med. Chem. Lett. 2007, 17, 2470–2473.
40. Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T. T.; Basu, A.; Costa, R. R.; Silva, J. M.; Sarafianos, S. G.; Noel, F. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucl. Acids Res. 2008, 36, 1482–1496.
41. Golisade, A.; Wiesner, J.; Herforth, C.; Jomaa, H.; Link, A. Anti-Malarial Activity of N6-Substituted Adenosine Derivatives. Bioorg. Med. Chem. 2002, 10, 769–777.
42. Kim, Y. A.; Sharon, A.; Chu, C. K.; Rais, R. H.; Al Safarjalani, O. N.; Naguib, N. M.; Kouni, M. H. Synthesis , biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. Biochem. Pharmacol. 2007, 73, 1558–1572.
43. Ivanov, A. V.; Smirnova, O. A.; Golubeva, N. A.; Ivanov, M. A.; Tunitskaya, V. L.; Shipitsyn, A. V.; Alexandrova, L. A. Base-modified ribonucleosides as potential anit-hepatitis C virus agents. Nucleic acids symp. series. 2008, 52, 619–620.
44. Kaye, P. T.; Musa, M. A. A convenient and improved Baylis–Hillman synthesis of 3-substituted 2H-1-benzopyran-2-ones. Synthesis 2002, 18, 2701–2706.
45. (a) http://accelrys.com/ (b) http://www.molsci.com.tw/index.html
46. Brooks, B. R.; Brooks, C. L.; Mackerell, A. D.; Nillson, L.; Petrelia, R. J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.; Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D. M.; Karplus, M. CHARMM: the biomolecular simulation program. J. Comput. Chem. 2009, 30, 1545–1614.
47. Kuhn, B.; Mohr, P.; Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 2010, 53, 2601–2611.
48. http://pubs.acs.org/page/joceah/submission/authors.html
49. Oliviero, G.; Amato, J.; Borbone, N.; D’Errico, S.; Piccialli, G.; Bucci, E.; Piccialli, V.; Mayol, L. Synthesis of 4-N-alkyl and ribose-modified AICAR analogues on solid support. Tetrahedron 2008, 64, 6475–6481.
50. Szarek, W. A.; Mario Pinto, B.; Iwakawa, M. Synthesis and biological activity of nucleoside analogs involving modifications in the carbohydrate ring. Can. J. Chem. 1985, 63, 2149–2161.
51. Casanova, E.; Perez-Perez, Maria-Juses.; Kappe, C. O. Microwave-assisted selective 5'-O-Trityl protection of inosine derivatives. Synlett. 2007, 11, 1733–1735.
52. Abramov, M.; Herdewijn, P. Synthesis and biological evaluation of inosine phosphonates. New J. Chem. 2010, 34, 875–876.
53. Luzzio, F. A.; Menes, M. E. A facile route to pyrimidine-based nucleoside olefins: application to the synthesis of d4T (Stavudine). J. Org. Chem. 1994, 59, 7267–7272.
54. Nakanishi, K.; Solomon, P. H. Infrared Absorption Spectroscopy, 2nd ed.; Holden-Day: Oakland, CA, 1977; p 38.
|